NICE Approves New Non-Hormonal Menopause Pill for NHS Patients

A significant milestone has been reached for menopausal women across England, with the National Institute for Health and Care Excellence (NICE) now recommending fezolinetant (marketed as Veoza) for NHS prescription. This non-hormonal daily tablet offers a new treatment pathway for around 500,000 eligible women experiencing moderate to severe menopausal symptoms when conventional hormone replacement therapy (HRT) is not appropriate.

Fezolinetant is a neurokinin 3 receptor antagonist—a medication that works by blocking specific nerve pathways in the brain responsible for triggering vasomotor symptoms such as hot flushes and night sweats. The once-daily 45mg tablet represents the first drug in this class to be approved for NHS use, marking a significant development in menopause treatment options.

Vasomotor symptoms affect approximately 70% of women going through menopause and can have profound impacts on daily functioning. Beyond the physical discomfort of sudden heat and sweating episodes, these symptoms can disrupt sleep patterns, affect concentration at work, strain relationships, and significantly diminish quality of life. For many women, the unpredictability and severity of symptoms create genuine challenges in managing their careers and personal wellbeing during an already complex life stage.

Whilst HRT remains the most effective treatment for menopausal symptoms, it is unsuitable for many women. Those with a personal history of breast cancer, blood clots (deep vein thrombosis or pulmonary embolism), certain heart conditions, or specific diabetes-related complications cannot safely use HRT. Additionally, some women choose not to take hormone-based treatments due to personal preference or concerns about potential side effects. Until now, treatment options for these groups have been limited.

The NICE recommendation is supported by evidence from three clinical trials: Daylight, Skylight 1, and Skylight 2. These studies demonstrated that fezolinetant significantly reduced the frequency and severity of hot flushes and night sweats compared to placebo. The medication was approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) in December 2023 and had initially been available only through private prescription at £44.80 per 28-tablet pack.

NICE previously reviewed fezolinetant in April 2025 and initially recommended against NHS provision. However, the final draft guidance released in March 2026 now supports its use, indicating that the cost-effectiveness estimates fall within the acceptable range for NHS resource allocation. This represents a positive outcome for women who had been waiting for broader access to this treatment option.

It is important to note that fezolinetant is not the only non-hormonal option available. Selective serotonin reuptake inhibitors (SSRIs) such as paroxetine, various other antidepressant medications, and gabapentin have all been used to manage menopausal symptoms, though they are generally considered less effective than HRT. The British Menopause Society notes that paroxetine at 10mg daily has the strongest evidence base amongst these alternatives.

Additionally, the MHRA has approved a second neurokinin antagonist, elinzanetant (marketed as Lynkuet), manufactured by Bayer. However, NICE has not yet begun the appraisal process that would determine whether this medication becomes available through the NHS.

Dr Sue Mann, National Clinical Director in Women’s Health for NHS England, welcomed the recommendation, describing fezolinetant as “another vital treatment option which could help hundreds of thousands of women experiencing menopause to better manage their symptoms and feel more in control of their health.” The approval provides clarity for GP practices and hospital specialists on when and how to offer this treatment to eligible patients.

Anita Powell, founder of The Menopause Alliance charity, acknowledged the importance of this decision whilst highlighting the broader systemic challenges. “In community settings, I meet women every week who are struggling with debilitating menopausal symptoms and limited treatment options,” Powell stated. “NICE’s guidance recognises this reality. The next step must be ensuring that local services are equipped to deliver timely, informed care so women do not continue to fall through the gaps.”

This final comment underscores an important reality: approval of a new medication is only the first step. Successful implementation requires that GP surgeries, community health centres, and specialist clinics have adequate resources, training, and capacity to assess women’s eligibility and initiate treatment appropriately.

Key Takeaways

• Fezolinetant is the first neurokinin 3 receptor antagonist approved for NHS use in treating moderate to severe menopausal hot flushes and night sweats
• Around 500,000 women in England and Wales are eligible for this treatment when HRT is unsuitable or undesired
• The medication is taken as a once-daily 45mg tablet and works by regulating brain signals that trigger vasomotor symptoms
• It can be prescribed for women with contraindications to HRT, including those with breast cancer history, blood clotting disorders, or certain cardiovascular conditions
• NHS implementation will depend on local service capacity and clinician training

What This Means for Kent Residents

Kent residents experiencing menopausal symptoms unsuitable for HRT should discuss fezolinetant with their GP practice. Kent and Medway NHS Trust services, alongside primary care providers across the county, will have access to prescribe this medication to eligible women. Those seeking support or information about menopause treatment options can contact their local GP surgery or ask for referral to NHS menopause clinics if available in their area. Women should have an open conversation with their healthcare provider about their symptoms, any contraindications to HRT, and whether fezolinetant might be an appropriate option for their individual circumstances.